The safety and efficacy of this investigational RSV vaccine have not been established in any country for any use.

Overview of Moderna’s Investigational RSV Vaccine (mRNA-1345) in Adults ≥ 60 Years of Age

Advisory Committee on Immunization Practices (ACIP)

Rituparna Das, MD, PhD
Feb 29, 2024
Outline of Presentation

- Overview of mRNA-1345, Moderna’s investigational RSV vaccine
- Pivotal Phase 2/3 trial
  - Efficacy
  - Safety
  - Immunogenicity
- Persistence of antibody and revaccination – Phase 1 trial
- Concomitant administration with influenza and COVID-19 vaccines
- Summary
Investigational RSV Vaccine (mRNA-1345) Designed to Encode for a Stabilized Prefusion F Glycoprotein

- LNP encapsulated mRNA-based vaccine encoding the RSV fusion (F) glycoprotein stabilized in the prefusion conformation
- Prefusion F elicits potent neutralizing antibody response\(^1,2\)
- Antibodies to the F protein cross-react between RSV-A and RSV-B
- RSV vaccine uses the same LNP as Moderna COVID-19 vaccines\(^3\)
- Phase 1: mRNA-1345 is well tolerated with persistent antibody levels through 12 months\(^4\)

Pivotal Safety and Efficacy Trial of RSV Vaccine, mRNA-1345 (Study 301)
Study Design

Study 301

Population
- Healthy adults including those with chronic, stable medical conditions, and/or frailty
- ≥ 60 years of age
- 22 countries (both Northern and Southern Hemisphere)

Regimen and follow-up
- Single-dose regimen (1:1 50 μg RSV vaccine or saline placebo)
- 24-month follow-up
- Weekly active RSV case surveillance performed throughout study to addresses unpredictability of RSV seasons following pandemic

Stratified by
- Age (60 - 74 and ≥ 75 years)
- Presence or absence of congestive heart failure or chronic obstructive pulmonary disease

clinicaltrials.gov NCT05127434 https://clinicaltrials.gov/ct2/show/NCT05127434
Enrollment Enriched for High-Risk Groups
Study 301

Individuals with Comorbidities

- COPD
- CHF
- Asthma
- Chronic respiratory disease
  - Diabetes
- Advanced liver disease
- Advanced renal disease

Frail Individuals

- Measured by Edmonton Frail Scale across 9 domains:
  - Cognition
  - General health status
  - Functional independence
  - Social support
  - Medication use
- Nutrition
- Mood
- Continence
- Functional performance

- 0-17 point scale
  - Fit (0–3)
  - Vulnerable (4–5)
  - Frail (6-17)

1 Chronic respiratory disease includes chronic pulmonary fibrosis (idiopathic and otherwise), restrictive lung disease, asbestosis, bronchiectasis, cystic fibrosis, pulmonary hypertension, sarcoidosis, and history of tuberculosis
Study Design – Randomization

Study 301

- No safety signals identified after DSMB review of Phase 2 safety data
- Allowed for seamless transition to start of Phase 3

Adults ≥ 60 Years
N = 36,557

Phase 2
United States
Initiated November 2021
N = 1,991

Investigational RSV Vaccine (mRNA-1345, 50 μg)
N = 993
Placebo
N = 998

Phase 3
Global Sites
Initiated February 2022
N = 34,566

Investigational RSV Vaccine (mRNA-1345, 50 μg)
N = 17,311
Placebo
N = 17,255

Clinicaltrials.gov NCT05127434 https://clinicaltrials.gov/ct2/show/NCT05127434
DSMB = Data Safety and Monitoring Board
36,557 Participants Enrolled in 22 Countries (as of April 30, 2023 data cutoff)

Study 301

269 Study Sites Across Northern and Southern Hemisphere

Number of participants in each country shown in parentheses

Canada (706)
United States (19,571)
Mexico (733)

Argentina (3,589)
Chile (679)
Colombia (2,625)
Costa Rica (208)
Panama (1,551)

South Africa (982)

Australia (256)
Bangladesh (2,421)
Japan (822)
New Zealand (299)
Singapore (8)
South Korea (27)
Taiwan (84)

Belgium (413)
Finland (96)
Germany (471)
Poland (346)
Spain (220)
United Kingdom (450)
Primary and Additional Efficacy Analyses

US 2021-2023 RSV Hospitalization Rates (RSV-NET) in Adults ≥ 65 Years

- RSV efficacy study conducted across 2021 – 2022 and 2022 – 2023 seasons
- >50% of participants enrolled in US
- Primary Analysis: Met success criteria
- Additional Analysis: 94% of participants followed for ≥ 6 months

*Median RSV hospitalization rate for 2016 – 2019. Data only collected from October to April each year.
Demographics of Study Participants

**Study 301**

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>RSV Vaccine (mRNA-1345) (N = 18,304)</th>
<th>Placebo (N = 18,253)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median Age, years</td>
<td>67</td>
<td>67</td>
</tr>
<tr>
<td>Male, n (%)</td>
<td>9,376 (51%)</td>
<td>9,277 (51%)</td>
</tr>
<tr>
<td>Age Group, n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>60 – 69 Years</td>
<td>11,348 (62%)</td>
<td>11,301 (62%)</td>
</tr>
<tr>
<td>70 – 79 Years</td>
<td>5,512 (30%)</td>
<td>5,500 (30%)</td>
</tr>
<tr>
<td>≥ 80 Years</td>
<td>1,444 (8%)</td>
<td>1,452 (8%)</td>
</tr>
<tr>
<td>Race/Ethnicity, n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>11,318 (62%)</td>
<td>11,290 (62%)</td>
</tr>
<tr>
<td>Black or African American</td>
<td>2,210 (12%)</td>
<td>2,175 (12%)</td>
</tr>
<tr>
<td>Asian</td>
<td>2,014 (11%)</td>
<td>2,001 (11%)</td>
</tr>
<tr>
<td>American Indian or Alaska Native</td>
<td>907 (5%)</td>
<td>897 (5%)</td>
</tr>
<tr>
<td>Native Hawaiian or Other Pacific Islander</td>
<td>28 (0.2%)</td>
<td>19 (0.1%)</td>
</tr>
<tr>
<td>Hispanic / Latino Ethnicity</td>
<td>6,118 (33%)</td>
<td>6,169 (34%)</td>
</tr>
</tbody>
</table>

Age, gender, race, and ethnicity balanced between vaccine and placebo recipients
Race/ethnicity generally representative of US population
Participants with Lower Respiratory Tract Disease (LRTD) Risk Factors and Comorbidities of Interest

Study 301

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>RSV Vaccine (mRNA-1345) (N = 18,304)</th>
<th>Placebo (N = 18,253)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CHF or COPD, n (%)</td>
<td>1,310 (7%)</td>
<td>1,316 (7%)</td>
</tr>
<tr>
<td>≥1 Comorbidity of Interest, n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>COPD, CHF, asthma, chronic respiratory disease¹, diabetes, advanced liver disease, advanced renal disease</td>
<td>5,417 (30%)</td>
<td>5,316 (29%)</td>
</tr>
<tr>
<td>Frailty², n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vulnerable (score of 4-5)</td>
<td>2,852 (16%)</td>
<td>2,917 (16%)</td>
</tr>
<tr>
<td>Frail (score of 6-17)</td>
<td>1,013 (6%)</td>
<td>1,033 (6%)</td>
</tr>
</tbody>
</table>

| Enrollment included those at highest risk of severe RSV                       |

¹. Chronic respiratory disease includes chronic pulmonary fibrosis (idiopathic and otherwise), restrictive lung disease, asbestosis, bronchiectasis, cystic fibrosis, pulmonary hypertension, sarcoidosis, and history of tuberculosis

². Based on 17-point Edmonton Frailty Score
Safety Data

Study 301

Safety Set – April 30, 2023 data cutoff

*Based on 6 months of follow-up for ~94% of participants*
Primary Safety Endpoints and Duration of Follow-up

Study 301

Active Safety Surveillance

- Solicited Local and Systemic Adverse Reactions
- Unsolicited Adverse Events
- Medically Attended AEs, Serious AEs Including Death, AEs Leading to Discontinuations
- Adverse Events of Special Interest (including Myocarditis, Pericarditis, Thrombocytopenia, Neurologic Events, and Anaphylaxis)

1. Neurologic events of interest include Guillain-Barre syndrome, acute disseminated encephalomyelitis, Bell’s palsy, and seizures
Solicited Local Reactions within 7 Days After RSV Vaccine vs Placebo

Study 301 - Solicited Safety Set

- Injection Site Pain
  - RSV: 55.9%
  - Placebo: 13.8%

- Injection Site Erythema
  - RSV: 2.0%
  - Placebo: 0.6%

- Injection Site Swelling
  - RSV: 3.7%
  - Placebo: <1%

- Axillary Swelling or Tenderness
  - RSV: 15.2%
  - Placebo: 6.1%

Mostly grade 1, onset day 1-2, median duration of 1-2 days for RSV vaccine

RSV vaccine, n=18174; placebo, n=18102
For placebo, grade 2 erythema and grade 2 and grade 3 swelling were < 1%
No grade 4 local adverse reactions
Solicited Systemic Reactions within 7 Days After RSV Vaccine vs Placebo

Study 301 - Solicited Safety Set

<table>
<thead>
<tr>
<th>Reaction</th>
<th>RSV Vaccine</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fever</td>
<td>2.8%</td>
<td>1.3%</td>
</tr>
<tr>
<td>Headache</td>
<td>26.7%</td>
<td>18.8%</td>
</tr>
<tr>
<td>Fatigue</td>
<td>30.8%</td>
<td>20.0%</td>
</tr>
<tr>
<td>Myalgia</td>
<td>25.6%</td>
<td>14.4%</td>
</tr>
<tr>
<td>Arthralgia</td>
<td>21.7%</td>
<td>14.0%</td>
</tr>
<tr>
<td>Nausea / Vomiting</td>
<td>7.0%</td>
<td>5.3%</td>
</tr>
<tr>
<td>Chills</td>
<td>11.6%</td>
<td>6.8%</td>
</tr>
</tbody>
</table>

Mostly grade 1, onset day 1-2, median duration of 1-2 days for RSV vaccine

RSV vaccine, n=18174; placebo, n=18102
Grade 4 fever was reported (mRNA-1345 [n=29] and placebo [n=35]); no other categories reported any grade 4 reactions
Unsolicited Adverse Events Within 28 Days After Injection, Regardless of Relationship to Vaccine/Placebo

Study 301 - Solicited Safety Set

<table>
<thead>
<tr>
<th>Safety Set</th>
<th>RSV Vaccine (mRNA-1345) (N = 18,245)</th>
<th>Placebo (N = 18,184)</th>
</tr>
</thead>
<tbody>
<tr>
<td>All, n (%)</td>
<td>3,749 (21%)</td>
<td>3,412 (19%)</td>
</tr>
<tr>
<td>Serious</td>
<td>115 (0.6%)</td>
<td>111 (0.6%)</td>
</tr>
<tr>
<td>Fatal</td>
<td>1 (&lt;0.1%)</td>
<td>6 (&lt;0.1%)</td>
</tr>
<tr>
<td>Medically-Attended</td>
<td>1,606 (9%)</td>
<td>1,531 (8%)</td>
</tr>
<tr>
<td>Leading to Study Discontinuation</td>
<td>2 (&lt;0.1%)</td>
<td>11 (&lt;0.1%)</td>
</tr>
<tr>
<td>Severe/≥ Grade 3</td>
<td>129 (0.7%)</td>
<td>135 (0.7%)</td>
</tr>
<tr>
<td>Non-Serious</td>
<td>3,634 (20%)</td>
<td>3,301 (18%)</td>
</tr>
<tr>
<td>Any Adverse Event of Special Interest (AESI)</td>
<td>3 (&lt;0.1%)</td>
<td>8 (&lt;0.1%)</td>
</tr>
</tbody>
</table>

No imbalances in any categories between vaccine and placebo recipients

Based on April 30, 2023 cutoff
Adverse Events of Special Interest (AESI)

Study 301

- **Neurological Disorders**
  - No cases of Guillain-Barre syndrome or acute disseminated encephalomyelitis (ADEM)
  - No imbalance observed for other neurological disorders including Bell’s palsy/facial paralysis

- **Cardiac Events**
  - No imbalance observed in cardiac arrhythmias such as atrial fibrillation
  - No CEAC adjudicated cases of:
    - Acute myocarditis in vaccine recipients
    - Acute pericarditis in vaccine recipients with onset < 42 days
Efficacy

Study 301
Key Efficacy Endpoints
Study 301

Primary Efficacy Objectives
Vaccine efficacy to prevent first episode of RSV-LRTD (Lower Respiratory Tract Disease) between 14 days and 12 months post-injection
- ≥ 2 signs/symptoms
- ≥ 3 signs/symptoms

Key Secondary Efficacy Objectives
Vaccine efficacy to prevent:
- First episode of RSV-ARD (Acute Respiratory Disease) between 14 days and 12 months post-injection
- First hospitalization associated with RSV-ARD or RSV-LRTD between 14 days and 12 months post-injection

Exploratory Endpoint
Vaccine efficacy against RSV-LRTD with shortness of breath (a surrogate measure of more severe disease)¹,²

Definitions of LRTD and ARD

**Study 301**

**RSV Lower Respiratory Tract Disease (LRTD)**
New or Worsening of ≥ 2 or ≥ 3 of Signs/Symptoms for ≥ 24 Hours

- Tachypnea
- Shortness of Breath
- Sputum Production
- Wheezing and/or rales and/or rhonchi
- Hypoxemia
- Fever and/or Cough
- Pleuritic Chest Pain

LRTD cases are a subset of the ARD cases

**RSV Acute Respiratory Disease (ARD)**
New or Worsening of ≥ 1 Signs/Symptoms for ≥ 24 Hours

- Sinus Pain
- Hoarseness
- Stuffy Nose
- Tachypnea
- Shortness of Breath
- Sputum Production
- Wheezing
- Sore Throat
- Runny Nose
- Chills
- Hypoxemia
- Fever
- Pleuritic Chest Pain

RSV surveillance was conducted year-round throughout study follow-up
Primary Analysis

**Study 301**
Per Protocol Analysis – November 30, 2022 data cutoff
Efficacy of mRNA-1345 Against RSV LRTD and RSV ARD among Adults ≥ 60 Years
Study 301 - Per Protocol Analysis

Vaccine efficacy for primary and key secondary endpoints (median 3.7 months) met lower bound of CI criterion (>20%)
- Regulatory criteria for licensure met

<table>
<thead>
<tr>
<th>Cases, n (%)</th>
<th>RSV Vaccine (mRNA-1345) (N = 17,572)</th>
<th>Placebo (N = 17,516)</th>
<th>Vaccine Efficacy (%) Based on Hazard Ratios¹</th>
</tr>
</thead>
<tbody>
<tr>
<td>RSV LRTD ≥ 2 symptoms</td>
<td>9 (0.05%)</td>
<td>55 (0.31%)</td>
<td>83.7% (66.0%, 92.2%)</td>
</tr>
<tr>
<td>RSV LRTD ≥ 3 symptoms</td>
<td>3 (0.02%)</td>
<td>17 (0.10%)</td>
<td>82.4% (34.8%, 95.3%)</td>
</tr>
<tr>
<td>RSV ARD</td>
<td>26 (0.15%)</td>
<td>82 (0.47%)</td>
<td>68.4% (50.9%, 79.7%)</td>
</tr>
</tbody>
</table>

1. Alpha adjusted CI: 95.88% for RSV LRTD ≥ 2 symptoms, 96.36% for RSV LRTD ≥ 3 symptoms, 95.0% for RSV ARD
Wilson et al. NEJM, 2023
### Vaccine Efficacy Against RSV-A and RSV-B by Endpoint

**Study 301 - Per-Protocol Efficacy Set**

#### Numbers of Events

<table>
<thead>
<tr>
<th></th>
<th>RSV Vaccine (mRNA-1345) (N = 17,572)</th>
<th>Placebo (N = 17,516)</th>
<th>Vaccine Efficacy (CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>RSV LRTD ≥ 2 Symptoms</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Overall</td>
<td>9</td>
<td>55</td>
<td>83.7% (66.0, 92.2)</td>
</tr>
<tr>
<td>RSV-A</td>
<td>3</td>
<td>36</td>
<td>91.7% (73.0, 97.4)</td>
</tr>
<tr>
<td>RSV-B</td>
<td>6</td>
<td>19</td>
<td>68.5% (21.1, 87.4)</td>
</tr>
<tr>
<td><strong>RSV LRTD ≥ 3 Symptoms</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Overall</td>
<td>3</td>
<td>17</td>
<td>82.4% (34.8, 95.3)</td>
</tr>
<tr>
<td>RSV-A</td>
<td>1</td>
<td>10</td>
<td>90.0% (22.0, 98.7)</td>
</tr>
<tr>
<td>RSV-B</td>
<td>2</td>
<td>7</td>
<td>71.5% (-37.0, 94.1)</td>
</tr>
<tr>
<td><strong>RSV-ARD</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Overall</td>
<td>26</td>
<td>82</td>
<td>68.4% (50.9, 79.7)</td>
</tr>
<tr>
<td>RSV-A</td>
<td>11</td>
<td>51</td>
<td>78.5% (58.8, 88.8)</td>
</tr>
<tr>
<td>RSV-B</td>
<td>15</td>
<td>31</td>
<td>51.7% (10.6, 73.9)</td>
</tr>
</tbody>
</table>

- Efficacy was observed for both RSV-A and RSV-B
- Fewer cases of LRTD ≥ 3 symptoms resulted in larger confidence intervals for both subtypes

Wilson et al. *NEJM*, 2023
### Vaccine Efficacy by Age, Comorbidities, and Frailty Against RSV LRTD ≥ 2 Symptoms

#### Study 301 - Per-Protocol Efficacy Set

**Primary Analysis**

<table>
<thead>
<tr>
<th>RSV LRTD with ≥ 2 Symptoms</th>
<th>Numbers of Events</th>
<th>Vaccine Efficacy (CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>RSV Vaccine (mRNA-1345) (N = 17,572)</td>
<td>Placebo (N = 17,516)</td>
</tr>
<tr>
<td>Overall</td>
<td>9 / 17,572</td>
<td>55 / 17,516</td>
</tr>
<tr>
<td>Age</td>
<td></td>
<td></td>
</tr>
<tr>
<td>60 – 69 Years</td>
<td>8 / 11,168</td>
<td>33 / 11,118</td>
</tr>
<tr>
<td>70 – 79 Years</td>
<td>1 / 5,440</td>
<td>22 / 5,416</td>
</tr>
<tr>
<td>≥ 80 Years</td>
<td>0 / 964</td>
<td>0 / 982</td>
</tr>
<tr>
<td>Comorbidities</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No Comorbidities</td>
<td>7 / 12,377</td>
<td>38 / 12,431</td>
</tr>
<tr>
<td>≥ 1 Comorbidities</td>
<td>2 / 5,195</td>
<td>17 / 5,085</td>
</tr>
<tr>
<td>Frailty Status</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fit (0-3)</td>
<td>8 / 13,396</td>
<td>45 / 13,250</td>
</tr>
<tr>
<td>Vulnerable/Frail (≥ 4)</td>
<td>0 / 3,781</td>
<td>6 / 3,858</td>
</tr>
</tbody>
</table>

- Case splits favorable for mRNA-1345 with respect to age, comorbidities, and frailty
- No cases observed in ≥ 80-year-olds

Wilson et al. NEJM, 2023; NE - nonestimable

Comorbidities include COPD, CHF, asthma, chronic respiratory disease, diabetes, advanced liver disease, advanced renal disease
### Study 301 - Post Hoc Analysis/Per Protocol Analysis

**Efficacy Against Severe (based on Shortness of Breath) and Medically Attended LRTD Among Adults ≥ 60 Years**

<table>
<thead>
<tr>
<th>Cases, n (%)</th>
<th>RSV Vaccine (mRNA-1345) (N = 17,572)</th>
<th>Placebo (N = 17,516)</th>
<th>Vaccine Efficacy (%) Based on Hazard Ratios (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>RSV-LRTD Associated Shortness of Breath</strong>(^1,2)</td>
<td>2 (0.01%)</td>
<td>15 (0.09%)</td>
<td><strong>86.7%</strong> (41.9%, 97.0%)</td>
</tr>
<tr>
<td><strong>Medically Attended RSV-LRTD</strong> (≥ 2 Symptoms and ER/Urgent Care)</td>
<td>0</td>
<td>5 (0.03%)</td>
<td>NE</td>
</tr>
</tbody>
</table>

- Shortness of breath is a key driver of seeking a higher level of care\(^1,2\)
- Vaccine is efficacious in preventing shortness of breath associated with RSV-LRTD
- Case split favorable for medically attended RSV-LRTD (ER/urgent care visits)

---

Based on Nov 30, 2022 cutoff; NE - nonestimable

Additional Analysis

**Study 301**

Per Protocol Analysis – April 30, 2023 data cutoff
Efficacy of mRNA-1345 Against RSV LRTD and RSV ARD among Adults ≥ 60 Years
Study 301 - Per Protocol Analysis

**Additional Analysis**

<table>
<thead>
<tr>
<th>Cases, n (%)</th>
<th>RSV Vaccine (mRNA-1345) (N = 18,112)</th>
<th>Placebo (N = 18,045)</th>
<th>Vaccine Efficacy (%) Based on Hazard Ratios (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>RSV LRTD ≥ 2 symptoms</td>
<td>47 (0.26%)</td>
<td>127 (0.70%)</td>
<td>63.3% (48.7%, 73.7%)</td>
</tr>
<tr>
<td>RSV LRTD ≥ 3 symptoms</td>
<td>19 (0.10%)</td>
<td>51 (0.28%)</td>
<td>63.0% (37.3%, 78.2%)</td>
</tr>
<tr>
<td>RSV ARD</td>
<td>86 (0.47%)</td>
<td>185 (1.03%)</td>
<td>53.9% (40.5%, 64.3%)</td>
</tr>
</tbody>
</table>

- Vaccine protection continues over a longer period (median 8.6 months) through high-transmission 2022/2023 RSV season
- Lower bound of the confidence interval continued to exceed 20%
Cumulative Incidence Curve – Efficacy Against RSV LRTD with ≥ 2 Symptoms among Adults ≥ 60 Years
Study 301 - Per-Protocol Efficacy Set

Additional Analysis

Vaccine Efficacy*
(95% CI)
63.3%
(48.7%, 73.7%)

- 8.6 months median follow-up (range 0.5-17.7 months)
- Separation in curves observed early and sustained through follow-up

Data cutoff date: Apr 30, 2023; *based on hazard ratio
Vaccine Efficacy Against RSV-A and RSV-B by Endpoint
Study 301 - Per-Protocol Efficacy Set

<table>
<thead>
<tr>
<th></th>
<th>Numbers of Events</th>
<th>Vaccine Efficacy (CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>RSV LRTD ≥ 2 Symptoms</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Overall</td>
<td>47</td>
<td>127</td>
</tr>
<tr>
<td>RSV-A</td>
<td>24</td>
<td>78</td>
</tr>
<tr>
<td>RSV-B</td>
<td>22</td>
<td>50</td>
</tr>
<tr>
<td><strong>RSV LRTD ≥ 3 Symptoms</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Overall</td>
<td>19</td>
<td>51</td>
</tr>
<tr>
<td>RSV-A</td>
<td>10</td>
<td>30</td>
</tr>
<tr>
<td>RSV-B</td>
<td>9</td>
<td>22</td>
</tr>
<tr>
<td><strong>RSV-ARD</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Overall</td>
<td>86</td>
<td>185</td>
</tr>
<tr>
<td>RSV-A</td>
<td>43</td>
<td>106</td>
</tr>
<tr>
<td>RSV-B</td>
<td>42</td>
<td>80</td>
</tr>
</tbody>
</table>

Additional Analysis

- Efficacy was observed for both RSV-A and RSV-B
### Vaccine Efficacy by Age, Comorbidities, and Frailty Against RSV LRTD ≥ 2 Symptoms

**Study 301 - Per-Protocol Efficacy Set**

<table>
<thead>
<tr>
<th>RSV LRTD with ≥ 2 Symptoms</th>
<th>Numbers of Events</th>
<th>Vaccine Efficacy (CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>RSV Vaccine (mRNA-1345) (N = 18,112)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Placebo (N = 18,045)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Overall</td>
<td>47/18,112</td>
<td>127/18,045</td>
</tr>
<tr>
<td>Age</td>
<td></td>
<td></td>
</tr>
<tr>
<td>60 – 69 Years</td>
<td>31/11,219</td>
<td>77/11,170</td>
</tr>
<tr>
<td>70 – 79 Years</td>
<td>10/5,464</td>
<td>45/5,439</td>
</tr>
<tr>
<td>≥ 80 Years</td>
<td>6/1,429</td>
<td>5/1,436</td>
</tr>
<tr>
<td>Comorbidities</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No Comorbidities</td>
<td>31/12,751</td>
<td>76/12,796</td>
</tr>
<tr>
<td>≥ 1 Comorbidities</td>
<td>16/5,361</td>
<td>51/5,249</td>
</tr>
<tr>
<td>Frailty Status</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fit (0-3)</td>
<td>37/13,417</td>
<td>104/13,274</td>
</tr>
<tr>
<td>Vulnerable/Frail (≥ 4)</td>
<td>9/3,817</td>
<td>17/3,884</td>
</tr>
</tbody>
</table>

- Case splits favorable for mRNA-1345 with respect to age, comorbidities, and frailty
- Too few cases in ≥ 80-year-olds to assess efficacy

**Additional Analysis**

Comorbidities include COPD, CHF, asthma, chronic respiratory disease, diabetes, advanced liver disease, advanced renal disease
Efficacy Against Severe LRTD and Hospitalizations Among Adults ≥ 60 Years
Study 301 - Post Hoc Analysis/Per Protocol Analysis

<table>
<thead>
<tr>
<th>Cases, n (%)</th>
<th>RSV Vaccine (mRNA-1345) (N = 18,112)</th>
<th>Placebo (N = 18,045)</th>
<th>Vaccine Efficacy (%) Based on Hazard Ratios (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>RSV-LRTD Associated Shortness of Breath(^1,2)</td>
<td>11 (0.06%)</td>
<td>43 (0.24%)</td>
<td>74.6% (50.7%, 86.9%)</td>
</tr>
<tr>
<td>RSV LRTD with ≥ 2 Symptoms and ER/Urgent Care</td>
<td>5 (0.03%)</td>
<td>13 (0.07%)</td>
<td>61.8% (-7.35, 86.45)</td>
</tr>
<tr>
<td>Hospitalizations</td>
<td>0 (0%)</td>
<td>2 (0.01%)</td>
<td>NE</td>
</tr>
</tbody>
</table>

- Shortness of breath is a key driver of seeking a higher level of care\(^1,2\)
- Vaccine is efficacious in preventing:
  - Shortness of breath associated with RSV-LRTD
  - Medically attended RSV-LRTD (ER/urgent care visits)
- 2 hospitalizations in placebo recipients (both >70 years with comorbid conditions [asthma]; both recovered)

Based on April 30, 2023 cutoff
NE - nonestimable
Immunogenicity

Study 301

Immunogenicity Subset
Neutralizing Antibody Response by RSV Subtype – Baseline and Day 29
Study 301 - Microneutralization Antibody (IU/mL)

Per Protocol Immunogenicity Set

- Participants had baseline titers consistent with prior exposure to RSV
- One dose of 50 µg of mRNA-1345 increased titers by:
  - >8-fold for RSV-A
  - >5-fold for RSV-B
Neutralizing Antibody Response by RSV Subtype and Age – Baseline and Day 29

Study 301 – Microneutralization Antibody (IU/mL)

Per Protocol Immunogenicity Set

- Baseline titers similar across age groups
- Day 29 titers and fold rise are similar across age groups
T-cell Responses Following Receipt of mRNA-1345
CRID-001 Study - 15 Adults, 50-75 Years Old

- Vaccine elicits persistent CD4+ and CD8+ T-cell responses

RSV-F antigen specific, Interferon-γ+ T-cells (intracellular cytokine staining assay)
Durability of RSV-A and RSV-B Neutralizing Antibody Response with mRNA-1345 and Revaccination
Study 101 – Adults 65-79 Years

- RSV-A and RSV-B neutralizing antibodies detectable at 12 months post-vaccination, 2-3 fold above baseline
- Revaccination at 12 months results in increase in GMT
- Revaccination at 1 and 2 years is being evaluated in Phase 3 studies

N = 14-18 adults
Simorellis et al, ESWI 2023
Concomitant Administration of RSV Vaccine (mRNA1345) with Quadrivalent Influenza Vaccine (Afluria) or Bivalent COVID-19 Vaccine (mRNA-1273.214)

Study 302, Parts A & B
Study 302: Safety and Immunogenicity Study of Concomitant Administration of mRNA-1345 with Quadrivalent Influenza Vaccine (Afluria) or COVID-19 Bivalent Vaccine in Adults ≥ 50

Part A

- **Group 1**: Planned Sample Size 420, Randomized 249
  - Day 1: RSV Vaccine + Placebo
  - Day 29: RSV Vaccine + Placebo

- **Group 2**: Planned Sample Size 600, Randomized 690
  - Day 1: RSV Vaccine + Quadrivalent Flu Vaccine
  - Day 29: RSV Vaccine + Quadrivalent Flu Vaccine

- **Group 3**: Planned Sample Size 600, Randomized 692
  - Day 1: Quadrivalent Flu Vaccine + Placebo
  - Day 29: Quadrivalent Flu Vaccine + Placebo

Part B

- **Group 1**: Planned Sample Size 560, Randomized 562
  - Day 1: RSV Vaccine + Placebo
  - Day 29: RSV Vaccine + COVID-19 Bivalent Vaccine

- **Group 2**: Planned Sample Size 560, Randomized 566
  - Day 1: RSV Vaccine + Placebo
  - Day 29: RSV Vaccine + COVID-19 Bivalent Vaccine

- **Group 3**: Planned Sample Size 560, Randomized 563
  - Day 1: COVID-19 Bivalent Vaccine + Placebo
  - Day 29: COVID-19 Bivalent Vaccine + Placebo

1. Due to randomization error, sample size lower than planned
Comparison of Day 29 Geometric Mean Titer Ratio (GMR) – Concomitant vs Nonconcomitant Administration of mRNA-1345 and Quadrivalent Influenza Vaccine Study 302, Part A

<table>
<thead>
<tr>
<th>Antibody</th>
<th>GMR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>RSV-A Neutralizing Antibody (IU/mL)</td>
<td>0.81 (0.67, 0.97)</td>
</tr>
<tr>
<td>RSV-B Neutralizing Antibody (IU/mL)</td>
<td>0.85 (0.73, 1.00)</td>
</tr>
<tr>
<td>Influenza A/H1N1 Antibody</td>
<td>0.89 (0.77, 1.03)</td>
</tr>
<tr>
<td>Influenza A/H3N2 Antibody</td>
<td>0.97 (0.86, 1.09)</td>
</tr>
<tr>
<td>Influenza B/Phuket Antibody</td>
<td>0.91 (0.81, 1.02)</td>
</tr>
<tr>
<td>Influenza B/Washington Antibody</td>
<td>0.93 (0.82, 1.05)</td>
</tr>
</tbody>
</table>

All GMR non-inferiority criteria met (LB of the 2-sided 95% CI of GMR > 0.667)
Comparison of Day 29 Geometric Mean Titer Ratio (GMR) – Concomitant vs Nonconcomitant Administration of mRNA-1345 and COVID-19 Bivalent Vaccine Study 302, Part B

<table>
<thead>
<tr>
<th>Antibody</th>
<th>GMR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>RSV-A Neutralizing Antibody (IU/mL)</td>
<td>0.80 (0.70, 0.90)</td>
</tr>
<tr>
<td>RSV-B Neutralizing Antibody (IU/mL)</td>
<td>0.89 (0.79, 1.00)</td>
</tr>
<tr>
<td>COVID-19 (Wuhan) (AU/ml)</td>
<td>0.96 (0.87, 1.06)</td>
</tr>
<tr>
<td>COVID-19 (Omicron) (AU/ml)</td>
<td>1.01 (0.89, 1.14)</td>
</tr>
</tbody>
</table>

All GMR non-inferiority criteria met (LB of the 2-sided 95% CI of GMR > 0.667)
Solicited Local Reactions within 7 Days After mRNA-1345 Alone or Co-administered with Quadrivalent influenza Vaccine (Afluria) in Adults ≥ 50
Study 302, Part A - Solicited Safety Set

<table>
<thead>
<tr>
<th>Reaction</th>
<th>mRNA-1345 + Afluria, n= 678</th>
<th>mRNA-1345 + placebo, n= 249</th>
<th>Afluria + placebo, n= 683</th>
</tr>
</thead>
<tbody>
<tr>
<td>Injection Site Pain</td>
<td>48%</td>
<td>47%</td>
<td>26%</td>
</tr>
<tr>
<td>Injection Site Erythema</td>
<td>1%</td>
<td>1%</td>
<td>2%</td>
</tr>
<tr>
<td>Injection Site Swelling</td>
<td>2%</td>
<td>3%</td>
<td>1%</td>
</tr>
<tr>
<td>Axillary Swelling or Tenderness</td>
<td>12%</td>
<td>15%</td>
<td>9%</td>
</tr>
</tbody>
</table>

Mostly grade 1, onset day 1-2, median duration of 2 days for RSV + Flu

mRNA-1345 + Afluria, n= 678; mRNA-1345 + placebo, n= 249; Afluria + placebo; n= 683
One grade 4 event (0.4%) of axillary swelling or tenderness in mRNA-1345 + placebo group
Solicited Systemic Reactions within 7 Days After mRNA-1345 Alone or Co-administered with Quadrivalent Influenza Vaccine in Adults ≥ 50 Study 302, Part A - Solicited Safety Set

Mostly grade 1, onset day 1-2, median duration of 2 days for RSV + Flu

- Fever: 3% (Grade 1), 7% (Grade 2), 2% (Grade 3 + 4)
- Headache: 23% (Grade 1), 25% (Grade 2), 17% (Grade 3 + 4)
- Fatigue: 26% (Grade 1), 25% (Grade 2), 22% (Grade 3 + 4)
- Myalgia: 24% (Grade 1), 23% (Grade 2), 14% (Grade 3 + 4)

- Arthralgia: 20% (Grade 1), 21% (Grade 2), 14% (Grade 3 + 4)
- Nausea / Vomiting: 9% (Grade 1), 11% (Grade 2), 7% (Grade 3 + 4)
- Chills: 9% (Grade 1), 11% (Grade 2), 7% (Grade 3 + 4)

mRNA-1345 + Afluria, n=678; mRNA-1345 + placebo, n=249; Afluria + placebo; n=683

Grade 4 fever reported in 1 recipient of mRNA 1345+ placebo
Solicited Local Reactions within 7 Days After mRNA-1345 Alone or Co-administered with COVID-19 Bivalent Vaccine in Adults ≥ 50 Study 302, Part B - Solicited Safety Set

Mostly grade 1, onset day 1-2, median duration of 2 days for RSV + COVID-19

mRNA-1345 + COVID-19, n= 558; mRNA-1345 + placebo, n= 555; COVID-19 + placebo; n= 557
No grade 4 events
Solicited Systemic Reactions within 7 Days After mRNA-1345 Alone or Co-administered with COVID-19 Bivalent Vaccine in Adults ≥ 50
Study 302, Part B - Solicited Safety Set

Mostly grade 1, onset day 1-2, median duration of 2 days for RSV + COVID-19

<table>
<thead>
<tr>
<th>Reaction</th>
<th>mRNA + flu</th>
<th>mRNA + placebo</th>
<th>Flu + placebo</th>
<th>mRNA + Flu + placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fever</td>
<td>8%</td>
<td>2%</td>
<td>3%</td>
<td>3%</td>
</tr>
<tr>
<td>Headache</td>
<td>32%</td>
<td>27%</td>
<td>30%</td>
<td>35%</td>
</tr>
<tr>
<td>Fatigue</td>
<td>41%</td>
<td>30%</td>
<td>33%</td>
<td>40%</td>
</tr>
<tr>
<td>Myalgia</td>
<td>40%</td>
<td>27%</td>
<td>31%</td>
<td>35%</td>
</tr>
<tr>
<td>Arthralgia</td>
<td>35%</td>
<td>22%</td>
<td>26%</td>
<td>35%</td>
</tr>
<tr>
<td>Nausea / Vomiting</td>
<td>10%</td>
<td>7%</td>
<td>9%</td>
<td>10%</td>
</tr>
<tr>
<td>Chills</td>
<td>22%</td>
<td>13%</td>
<td>17%</td>
<td>22%</td>
</tr>
</tbody>
</table>

mRNA-1345 + COVID-19 vaccine, n= 558; mRNA-1345 + placebo, n= 555; COVID-19 vaccine + placebo; n= 557
Grade 4 fever reported in 1 recipient of COVID-19 + placebo
Safety Events of Interest – Study of Concomitant Administration of mRNA-1345 with Influenza or COVID-19 Vaccine

Study 302 A and B – Based on 6 Months Follow-up

Safety Set

- No reports of:
  - Deaths, SAEs, or AESIs as assessed as related by the investigator
  - Anaphylaxis
  - Guillain Barre Syndrome
  - Acute disseminated encephalomyelitis (ADEM)
  - Bell’s palsy/facial paralysis
  - Acute myocarditis or acute pericarditis
SUMMARY
## Summary

**Investigational RSV Vaccine (mRNA-1345)**

### Safety
- Vaccine generally well tolerated in >19,500 individuals
- No GBS, no ADEM, or other safety concerns

### Efficacy
- Vaccine efficacious; met all regulatory criteria for licensure
- Continued to be efficacious through median 8.6 months follow-up
- Shown to prevent severe RSV disease (based on analysis of shortness of breath and medically attended RSV-LRTD)

### Immunogenicity
- Strong humoral and cellular immune responses
- Detectable through 12 months post-vaccination; boosting observed with 1-year revaccination
- RSV-A & RSV-B nAb responses similar across age groups, including those ≥ 80 years old

### Concomitant Administration
- Pre-specified immunogenicity criteria met & and no new safety signals observed with concomitant administration of mRNA-1345 with influenza vaccine or mRNA-COVID-19 vaccine
THANK YOU!

- Investigators
- Study site personnel
- Laboratory personnel
- Most importantly, the individuals who participated in these trials